2026 Mid-terms: Voting for the Future

By MIKE MAGEE This week, New York Times political columnist, Linda Kindler reflected on “How Silicon Valley Stole the Future.” Signaling that this wasn’t simply another article on the binary choices of an AI world – or as she put it “either a world in which A.I. has eliminated all jobs, unleashed bioengineered viruses and…

Read More

BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year. The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting…

Read More